New to Meducation?
Sign up
Already signed up? Log In

Category

1
1
32

Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC, Case 2 (video)

<p>Case discussion with Drs. Tom Hensing of in Chicago &amp; David Jackman in Boston, discussing practical issues around molecular marker testing &amp; recommended treatments for first line &amp; maintenance therapy for an ex-smoker with a lung adenocarcinoma.</p>  
Howard (Jack) West, MD
almost 9 years ago
2
1
28

Expert Round Table with Drs. Hensing and Jackman on Molecular Markers and Sequencing of Therapy for Advanced NSCLC, Case 2 (audio)

<p>Case discussion with Drs. Tom Hensing of in Chicago &amp; David Jackman in Boston, discussing practical issues around molecular marker testing &amp; recommended treatments for first line &amp; maintenance therapy for an ex-smoker with a lung adenocarcinoma.</p>  
Howard (Jack) West, MD
almost 9 years ago
5
1
22

Expert Round Table on Managing Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly and Frail Patients (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre;">Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.<br /></span></p>  
Howard (Jack) West, MD
almost 9 years ago
6
1
16

Expert Round Table on Managing Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly and Frail Patients (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre;">Case discussion with Drs. Paul Hesketh of the Lahey Clinic and Karen Kelly of Kansas University Medical Center, covering question of optimal treatment for patients with advanced NSCLC who are elderly or have a marginal performance status.<br /></span></p>  
Howard (Jack) West, MD
almost 9 years ago
1
1
59

Should Surgery be Considered for Very Limited Small Cell Lung Cancer? (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Howard (Jack) West, medical oncologist, President &amp; CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).</span></p>  
Howard (Jack) West, MD
almost 9 years ago
2
1
54

Should Surgery be Considered for Very Limited Small Cell Lung Cancer? (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Howard (Jack) West, medical oncologist, President &amp; CEO of GRACE, reviews the debate about whether surgery should have a role in managing early small cell lung cancer (SCLC).</span></p>  
Howard (Jack) West, MD
almost 9 years ago
5
1
37

Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
6
1
56

Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
3
2
38

ALK gene rearrangements, ALK inhibitors, and the Lung Cancer Revolution, by Dr. D. Ross Camidge (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. D. Ross Camidge, medical oncologist at the University of Colorado, provides an overview of the newly identified ALK gene rearrangements, novel therapy to target this, and the promise of molecular oncology.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
4
1
24

ALK gene rearrangements, ALK inhibitors, and the Lung Cancer Revolution, by Dr. D. Ross Camidge (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. D. Ross Camidge, medical oncologist at the University of Colorado, provides an overview of the newly identified ALK gene rearrangements, novel therapy to target this, and the promise of molecular oncology.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
9
1
50

Interview with Dr. Kristin Manning, Part 1: Screening, Workup, and Follow-Up of Lung Cancer (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Kristin Manning, expert radiologist at Seattle Radiology, discusses work on lung cancer screening, the features of a pulmonary nodule that raise and lower suspicion for lung cancer, and other aspects of initial and follow-up imaging for lung cancer.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
10
1
49

Interview with Dr. Kristin Manning, Part 1: Screening, Workup, and Follow-Up of Lung Cancer (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Kristin Manning, expert radiologist at Seattle Radiology, discusses work on lung cancer screening, the features of a pulmonary nodule that raise and lower suspicion for lung cancer, and other aspects of initial and follow-up imaging for lung cancer.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
11
1
64

IInterview with Dr. Matthew Horton, Pathologist Part 3: Defining Lung Cancer with Molecular Markers (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses new approaches in molecular profiling of lung cancers.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
12
1
41

Interview with Dr. Matthew Horton, Pathologist Part 3: Defining Lung Cancer with Molecular Markers (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses new approaches in molecular profiling of lung cancers.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
13
1
22

The Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (audio)

<p><span style="font-family: Times; font-size: medium;"> </span></p <div style="color: #000000; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 10px; background-image: initial; background-repeat: initial; background-attachment: initial; background-color: #ffffff; background-position: initial initial; margin: 8px;" <p><span style="font-family: arial, sans, sans-serif; font-size: small;"><span style="font-size: 13px; white-space: pre-wrap;"><span style="font-family: Times; font-size: medium; white-space: normal;"> </span></span></span></p <span style="font-family: arial, sans, sans-serif; font-size: small;" <div style="color: #000000; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 10px; background-image: initial; background-repeat: initial; background-attachment: initial; background-color: #ffffff; background-position: initial initial; margin: 8px;" <p><span style="font-family: arial, sans, sans-serif; font-size: small;"><span style="font-size: 13px; white-space: pre-wrap;">Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.</span></span></p </div </span <p>&nbsp;</p </div <p>&nbsp;</p>  
Howard (Jack) West, MD
almost 9 years ago
0
1
28

The Emerging Role of Molecular Markers in Non-Small Cell Lung Cancer: a Webinar by Dr. Nathan Pennell (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, reviews the current evidence and future directions for use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
1
1
60

Interview with Dr. Matthew Horton, Pathologist Part 2: Neuroendocrine Lung Tumors and Bronchioloalveolar Carcinoma (audio)

<p><font face="'Lucida Grande', Arial, Helvetica, sans-serif" size="3"><span style="font-size: 11px; white-space: pre-wrap;"><span style="font-family: Times; font-size: medium; white-space: normal;" <div style="color: #000000; font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 10px; background-image: initial; background-repeat: initial; background-attachment: initial; background-color: #ffffff; background-position: initial initial; margin: 8px;" <p><font face="'Lucida Grande', Arial, Helvetica, sans-serif" size="3"><span style="font-size: 11px; white-space: pre-wrap;"><span style="font-family: arial, sans, sans-serif; font-size: 13px;">Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the neuroendocrine spectrum of lung tumors and the evolving views on bronchioloalveolar carcinoma (BAC).</span></span></font></p </div </span></span></font></p>  
Howard (Jack) West, MD
almost 9 years ago
2
1
70

Interview with Dr. Matthew Horton, Pathologist Part 2: Neuroendocrine Lung Tumors and Bronchioloalveolar Carcinoma (video)

<p><font face="'Lucida Grande', Arial, Helvetica, sans-serif" size="3"><span style="font-size: 11px; white-space: pre-wrap;"><span style="font-family: arial, sans, sans-serif; font-size: 13px;">Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the neuroendocrine spectrum of lung tumors and the evolving views on bronchioloalveolar carcinoma (BAC).</span></span></font></p>  
Howard (Jack) West, MD
almost 9 years ago
3
0
133

Interview with Dr. Matthew Horton, Pathologist Part 1: Basics of Non-Small Cell Lung Cancer Subtypes (audio)

Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the basic subtypes of non-small cell lung cancer (NSCLC), methods of interpreting NSCLC histology, and the changing importance of pathology in NSCLC management.  
Howard (Jack) West, MD
almost 9 years ago
4
1
82

Interview with Dr. Matthew Horton, Pathologist Part 1: Basics of Non-Small Cell Lung Cancer Subtypes (video)

Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the basic subtypes of non-small cell lung cancer (NSCLC), methods of interpreting NSCLC histology, and the changing importance of pathology in NSCLC management.  
Howard (Jack) West, MD
almost 9 years ago